FridayAug 19, 2022 12:24 pm

Women May Benefit Greatly from Psychedelics Renaissance

Over the past few years, there has been significantly increased interest in psychedelics among the scientific and mainstream community. Initial studies have found that they can alleviate mental health issues such as anxiety, depression and PTSD, and the media has been full of stories of people who benefited from psychedelic-assisted therapies. Research shows that veterans and terminal patients stand to benefit a great deal from psychedelic therapies because those treatments have been found to be effective at mitigating conditions that affect these two groups. However, what a lot of people may not know is that women could also benefit greatly…

Continue Reading

ThursdayAug 18, 2022 4:04 pm

Study Suggests LSD May Boost Learning, Memory by Enhancing Neural Plasticity

Psychedelic research has seen a significant surge in the past few years amid increased interest in psychedelics among the scientific community and the general public. Companies such as Mind Medicine (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) are developing psychedelic-inspired medicines and therapies to address addiction and mental health disorders. Studies have found that psychedelics have potential as alternative treatments for mental health conditions such as major depressive disorder and post-traumatic stress disorder (“PTSD”). Researchers have stepped up their efforts to study the potential benefits of psychedelics. New research has uncovered a possible link between lysergic acid diethylamide, or "LSD” and…

Continue Reading

WednesdayAug 17, 2022 1:35 pm

Psychedelics Advocates Put DEA Under Pressure Over Right to Try Laws

As per the federal and state Right-to-Try laws, terminally ill patients in the United States are allowed access to experimental drugs that have advanced past phase I testing but still haven’t received approval from the U.S. Food and Drug Administration. In 2018, 41 states had passed right-to-try laws on top of the federal Right to Try Act, meaning a majority of Americans could access unapproved drugs should they need them. With psychedelics currently experiencing a surge in mainstream and scientific interest due to their potential as alternative mental health treatments, there has been increased interest in the mind-altering drugs for…

Continue Reading

WednesdayAug 17, 2022 9:30 am

Silo Pharma Inc. (SILO): Promising Psylocibin Study Ongoing with UCSF

Company entered scientific research agreement with UCSF in June 2021 to study psilocybin effects on various inflammatory conditions Silo Pharma (OTCQB: SILO), recently announced that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients as part of a scientific research agreement (“SRA”) entered with Silo in June, 2021 to “to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain.  “Successful dosing and collection of blood samples from enrolled patients is an important milestone that demonstrates the progress being made…

Continue Reading

TuesdayAug 16, 2022 2:48 pm

Important Clinical Trials That May Result in Psychedelic Legalization

Initial studies have found that certain psychedelics have plenty of potential as treatments for mental health conditions such as post-traumatic stress disorder (PTSD) and major depressive disorder. Furthermore, activists across the country have put forth a variety of measures to decriminalize psychedelics, with cities such as Denver moving to decriminalize all psychedelics. But before psychedelics can be approved for widespread medical use, they will have to go through the clinical trial system successfully. This process involves three phases: phase I trials where animals are used to test the efficacy and safety of drugs; phase 2 trials involving several dozen patients…

Continue Reading

MondayAug 15, 2022 1:16 pm

Second Psychedelics Initiative Fails to Qualify for Colorado Ballot

Psychedelic enthusiasts, activists and researchers in Colorado will be sad to know that there won’t be two measures to legalize psychedelics on the November ballot. Two separate campaigns have pushed their own psychedelic measures since the start of the year, with only one campaign managing to collect enough signatures to qualify for the ballot. In late July, activists behind the Natural Medicine Health Act submitted around 100,000 signatures to the secretary of state’s office. The measure wants to legalize the possession of specific psychedelics, seal the records of people with prior psychedelic convictions and create a framework for psilocybin treatments.…

Continue Reading

FridayAug 12, 2022 2:06 pm

Psilocybin Lawsuit Filed in Canada May Boost Global Psychedelics Reform Efforts

Canada banned psychedelics more than 30 years ago, outlawing the production, sale and use of psychedelics, including psilocybin, for decades. Most countries around the world followed suit and banned psychedelics. However, psychedelic drugs were still quite popular despite being prohibited due to their mind-altering effects. In recent years, this mainstream popularity has reached an explosive level, especially regarding psychedelics' ability to treat mental health conditions, resulting in a surge in psychedelic research. A new psilocybin lawsuit in Canada now has the potential to spur a wave of psychedelics reform not only in Canada but in the United States as well.…

Continue Reading

ThursdayAug 11, 2022 12:59 pm

Five Great Podcasts for Those Interested in Psychedelics

Psychedelics have experienced a renaissance in recent years as public and scientific interest in mind-altering drugs has grown. Now researchers across the country are running studies to determine whether psychedelics have medical potential, specifically their ability to treat mental health conditions such as major depressive disorder and post-traumatic stress disorder (PTSD). Research into psychedelics is a relatively new and exciting field that is predicted to play a major role in mental health treatments over the next decade. Furthermore, given how popular these mind-altering drugs are among the mainstream public and the scientific community, there are plenty of credible media sources…

Continue Reading

WednesdayAug 10, 2022 2:34 pm

Leading Neuroscientist Explains How Psychedelics Alters the Brain

We have seen interest in psychedelics grow significantly these last few years as more studies into the therapeutic potential of the substance has been conducted. Psychedelics are substances that alter the function of an individual’s brain when ingested. This may result in changes in their mood, perception and cognitive processes. Common psychedelics include mescaline, psilocybin, ayahuasca and peyote. Despite the fact that humans have known about and used these hallucinogens for millennia, there is still a lot we are uncertain about when it comes to these substances and how they can benefit us. Below, we look at what we’ve learned…

Continue Reading

TuesdayAug 09, 2022 1:59 pm

Compass Pathways to Begin New Phase 2 Psychedelic Trial for Anorexia

Compass Pathways PLC (NASDAQ: CMPS) is a mental health care company that is focused on improving patient access to evidence-based innovation in mental health. The company’s stock, which trades as CMPS on the NASDAQ has been performing well, with many attributing this positive performance to the appointment of a new CEO. The company recently announced that it would be launching a new phase 2 trial on the use of its COMP360 formulation in treating anorexia. The company will conduct the trial at various prestigious research institutions in the United States and the United Kingdom, including Columbia University’s Irving Medical Center,…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050